| Mr Fred Gary Glasser, MD | |
|
297 Mineola Blvd, Mineola, NY 11501-1502 | |
| (516) 294-1377 | |
| (516) 294-5574 |
| Full Name | Mr Fred Gary Glasser |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 297 Mineola Blvd, Mineola, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336113141 | NPI | - | NPPES |
| 01069718 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 158600 (New York) | Primary |
| Entity Name | Advanced Pulmonary Diagnostics, Rllp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265408538 PECOS PAC ID: 3476444555 Enrollment ID: O20040320000582 |
News Archive
Defects in a protein that functions as a dietary fat sensor may be a cause of obesity and liver disease, according to a study published in the journal Nature, led by researchers at Imperial College London. The findings highlight a promising target for new drugs to treat obesity and metabolic disorders.
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Mylan Inc. today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes are being offered as additional notes under an existing indenture under which Mylan issued $700 million aggregate principal amount of 7.875% Senior Notes due 2020 on May 19, 2010. The notes to be issued in this offering and the previously issued 7.875% Senior Notes due 2020 will be treated as a single class of notes under the indenture.
The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.
› Verified 5 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
Defects in a protein that functions as a dietary fat sensor may be a cause of obesity and liver disease, according to a study published in the journal Nature, led by researchers at Imperial College London. The findings highlight a promising target for new drugs to treat obesity and metabolic disorders.
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Mylan Inc. today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes are being offered as additional notes under an existing indenture under which Mylan issued $700 million aggregate principal amount of 7.875% Senior Notes due 2020 on May 19, 2010. The notes to be issued in this offering and the previously issued 7.875% Senior Notes due 2020 will be treated as a single class of notes under the indenture.
The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.
› Verified 5 days ago
| Entity Name | Winthrop Community Medical Affiliates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457873077 PECOS PAC ID: 5698092385 Enrollment ID: O20150317001669 |
News Archive
Defects in a protein that functions as a dietary fat sensor may be a cause of obesity and liver disease, according to a study published in the journal Nature, led by researchers at Imperial College London. The findings highlight a promising target for new drugs to treat obesity and metabolic disorders.
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Mylan Inc. today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes are being offered as additional notes under an existing indenture under which Mylan issued $700 million aggregate principal amount of 7.875% Senior Notes due 2020 on May 19, 2010. The notes to be issued in this offering and the previously issued 7.875% Senior Notes due 2020 will be treated as a single class of notes under the indenture.
The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Fred Gary Glasser, MD 297 Mineola Blvd, Mineola, NY 11501-1502 Ph: (516) 294-1377 | Mr Fred Gary Glasser, MD 297 Mineola Blvd, Mineola, NY 11501-1502 Ph: (516) 294-1377 |
News Archive
Defects in a protein that functions as a dietary fat sensor may be a cause of obesity and liver disease, according to a study published in the journal Nature, led by researchers at Imperial College London. The findings highlight a promising target for new drugs to treat obesity and metabolic disorders.
"Optimism and momentum has been building around the real possibility that an AIDS-free generation is imminent. Yet, the most recent estimates of HIV prevalence and incidence and of AIDS-related mortality released by UNAIDS, together with data from the Global Burden of Disease Study 2010 in the Lancet, make it clear that AIDS is not over," UNAIDS Executive Director Michel Sidibe; Peter Piot, director of the London School of Hygiene and Tropical Medicine; and Mark Dybul, incoming executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, write in a Lancet opinion piece.
Mylan Inc. today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes are being offered as additional notes under an existing indenture under which Mylan issued $700 million aggregate principal amount of 7.875% Senior Notes due 2020 on May 19, 2010. The notes to be issued in this offering and the previously issued 7.875% Senior Notes due 2020 will be treated as a single class of notes under the indenture.
The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.
› Verified 5 days ago
Dr. Marlene Martins Lobato, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 173 Mineola Blvd, Suite 403, Mineola, NY 11501 Phone: 516-741-8891 Fax: 516-741-8829 | |
Michael Garrison, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Old Country Rd, Suite 450, Mineola, NY 11501 Phone: 516-663-9500 Fax: 516-663-4613 | |
Dr. Anupama Ananda, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 190 Willis Ave, Suite 210, Mineola, NY 11501 Phone: 516-739-7290 Fax: 516-793-7291 | |
Mr. Jeffrey Liu, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 297 Mineola Blvd, Mineola, NY 11501 Phone: 516-294-1377 Fax: 516-294-5574 | |
Dr. Jonathan Shulman, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 259 1st St, Mineola, NY 11501 Phone: 516-663-2381 | |
John I Hogan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plz N Ste 432, Mineola, NY 11501 Phone: 516-663-2507 | |
Dr. Anthony Massimillo, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 300 Old Country Rd Ste 31, Mineola, NY 11501 Phone: 516-294-9380 Fax: 516-294-5351 |